ADA assays for high-dose biologics: redefining drug tolerance through clinical insights

Area of Science:

• Biopharmaceutical development
• Immunogenicity assessment
• Assay validation

Background:

• Anti-drug antibody (ADA) assay validation is critical for biologics, with regulatory agencies (EMA, FDA) requiring drug tolerance.
• Assessing drug tolerance must align with actual clinical use for patient care.
• High circulating drug levels and complex target biology present challenges in ADA assay development for biologics.

Purpose of the Study:

• To develop and validate an anti-drug antibody (ADA) assay for a fully human monoclonal antibody in oncology.
• To address challenges of high drug concentrations and target biology in assay development.
• To ensure the assay's drug tolerance and sensitivity are clinically relevant for patient management.

Main Methods:

• Tested various ADA assay formats using multiple positive controls and drug concentrations.
• Mimicked real-world drug exposure and drug-to-ADA ratios to characterize assay performance.
• Evaluated assay sensitivity and drug tolerance using clinically relevant drug and ADA concentrations.

Main Results:

• Assay performance varied with different positive controls, highlighting the importance of control selection.
• An assay initially showing low drug tolerance improved with alternative controls.
• Clinically relevant concentrations confirmed meaningful assay sensitivity and drug tolerance.

Conclusions:

• A patient-oriented strategy for ADA assay validation ensures meaningful results for therapeutic decisions.
• Selecting appropriate positive controls and using clinically relevant concentrations are key for robust drug tolerance.
• Collaboration with health authorities ensures alignment on performance criteria and interpretation for biologics therapy.